L. Daniel Browne
2017
In 2017, L. Daniel Browne earned a total compensation of $3.4M as President and Chief Executive Officer at Revance Therapeutics, a 17% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $466,038 |
|---|---|
| Option Awards | $1,905,694 |
| Salary | $525,300 |
| Stock Awards | $508,260 |
| Total | $3,405,292 |
Browne received $1.9M in option awards, accounting for 56% of the total pay in 2017.
Browne also received $466K in non-equity incentive plan, $525.3K in salary and $508.3K in stock awards.
Rankings
In 2017, L. Daniel Browne's compensation ranked 3,108th out of 14,666 executives tracked by ExecPay. In other words, Browne earned more than 78.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,108 out of 14,666 | 79th |
Division Manufacturing | 1,072 out of 5,768 | 81st |
Major group Chemicals And Allied Products | 292 out of 2,074 | 86th |
Industry group Drugs | 223 out of 1,730 | 87th |
Industry Pharmaceutical Preparations | 177 out of 1,329 | 87th |
Source: SEC filing on March 20, 2018.
Browne's colleagues
We found three more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2017.